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Purpose
To investigate the relationship between tumor-associated
CD40 expression, RCC patient survival and tumor stage.
Experimental design
The expression of CD40, TUNEL and CD8 in human
renal cell carcinomas was analyzed by immunohisto-
chemistry. Computer-assisted quantitation of protein
expression was used to correlate results with patient
survival and tumor stage.
Results
We show for the first time that tumor-associated CD40
expression correlates with prolonged survival in RCC
patients. CD40 also correlated with TUNEL and CD8
staining in tumor tissues. No correlation was observed
between CD40 and tumor stage.
Conclusions
Our results suggest CD40 may be a prognostic biomar-
ker indicative of prolonged RCC patient survival. Strate-
gies that up-regulate CD40 expression in some RCC
patients might lead to improved survival. The further
development and use of agonistic CD40 antibodies for
treatment of RCC is warranted.
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